Analysts Offer Insights on Healthcare Companies: Cryolife (NYSE: CRY), Verona Pharma Plc (NASDAQ: VRNA) and Curis Inc (NASDAQ: CRIS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cryolife (NYSE: CRY), Verona Pharma Plc (NASDAQ: VRNA) and Curis Inc (NASDAQ: CRIS) with bullish sentiments.

Cryolife (NYSE: CRY)

In a report released today, Jason Mills from Canaccord Genuity reiterated a Buy rating on Cryolife (NYSE: CRY), with a price target of $28. The company’s shares opened today at $19.40.

Mills said:

“We reiterate our BUY rating on CRY, taking our target price on the stock to $28 (from $25). The punch line is we think management will execute well in 2018, specifically as it relates to integration of the JOTEC acquisition (note: deal closed ahead of schedule on 12/1/17 and contributed more to Q4 than expected), which portends slight top & bottom line upside in 2018. However, even more importantly, we think if management simply executes within the guiderails of its guidance for 2018 (discussed below), it will set the stage for accelerating revenue growth and gross/operating margin expansion in 2019 and 2020. To wit, we note the firm communicated very positive progress on a number of important pipeline projects on the Q4 call. As for the Q4 print, CRY capped off an eventful 2017 with strong Q4 numbers that exceeded us/consensus on the top line and exceeded consensus on the bottom line by a handsome margin.”

According to TipRanks.com, Mills is a top 100 analyst with an average return of 24.6% and a 75.0% success rate. Mills covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Obalon Therapeutics Inc, and Boston Scientific Corp.

Currently, the analyst consensus on Cryolife is Moderate Buy and the average price target is $25.75, representing a 32.7% upside.

In a report released today, Northland Securities also maintained a Buy rating on the stock with a $23.50 price target.
Verona Pharma Plc (NASDAQ: VRNA)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Verona Pharma Plc (NASDAQ: VRNA), with a price target of $48. The company’s shares opened today at $17, close to its 52-week high of $17.50.

According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 10.6% and a 42.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Catabasis Pharmaceuticals.

Currently, the analyst consensus on Verona Pharma Plc is Strong Buy and the average price target is $34.33, representing a 101.9% upside.

In a report issued on March 2, Stifel Nicolaus also reiterated a Buy rating on the stock with a $25 price target.
Curis Inc (NASDAQ: CRIS)

Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Curis Inc (NASDAQ: CRIS) today. The company’s shares opened today at $0.64, close to its 52-week low of $0.47.

According to TipRanks.com, Shibutani is a 5-star analyst with an average return of 25.2% and a 52.1% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Lexicon Pharmaceuticals, and Five Prime Therapeutics.

Curis Inc has an analyst consensus of Moderate Buy.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.